Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
think youll be very upset on avct soon. i free carried my shares at 187p if what i believe is about to happen happens i may buy all back. lets see.
Only if you do you cheeky git !!! <(U.U)>
What people
Many don't realise antibody testing will be a routine in every country for many years to come. This is the only tool left allowing people to go to work and speed up recovery. Without a vaccine, which may never come, how countries will act without anything to protect their citizens ?
Novice - stop wasting your time writing this stuff.
people are switching from covid 19 stocks to normal recovery stocks
Clearly sentiment is waning today across this sector, maybe people are getting snow blindness of constant drip over the last 10-12 weeks, majority of bio's down heavily including avct and ncyt and SNG etc,etc all down about 7 to 10% if not more.
too many people with too much time on their hands. need to walk away and smell the roses and listen to the birdsong for the rest of the day...
Just keep buying folks
So we were right that new features that link test kit to app and update NHS have been added. I said yesterday, addition of new features (to original spec) may be why we have to wait a bit longer. I think that is why they are confident on the product working to expected level and only thing left may be the integration to app and central NHD database. I have no doubt they will get it done. I have no doubt it will be the best in the world. I have no doubt there is a lot to gain here. This is a cheap entry.
Press Release from UK-RTC (issued on 3 June 2020)
The UK-RTC has made significant progress in developing a COVID-19 lateral flow antibody test that can be used by people in their homes, since its inception 7 weeks ago. In addition, we have also made progress with the regulatory and logistics challenges needed to be overcome to support the Government in deploying the test directly to individuals across the UK.
With regards to the test progress, we are now consistently picking up positive samples across the range, including weak positives, whilst ensuring negative samples are not detected. We have conducted a small-scale study of 66 samples and results suggest the test is performing in line with design requirements. We expect to reach design freeze in June, which will allow us to move onto scale up, verification and validation activities, prior to the test being made available for manufacture.
In parallel with the above activities, we are working with Government and regulatory authorities to ensure proper approval of the test as quickly as possible.
The consortium is working with NHSX to develop a test specific app and digital service that will facilitate use and reading of the test device. This will have the ability to integrate with NHS systems and update records.
Finally, given the scale of the potential demand for the test within the UK, critical planning around supply chain logistics is also well under way, which will ensure a smooth introduction of the test directly to the public.
This is a very complex project that is being completed at extraordinary speed, compared to a normal test development programme, but thanks to the creative and hard work of everyone involved we remain on track to deliver a test to the UK that will make a significant difference to the approach needed to manage Covid-19 infections.